Related Experiment Video
Updated: Jan 30, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies
Ahmad Jayedi1, Kazem Rahimi2,3, Leonelo E Bautista4
1Food (salt) Safety Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Insights
Elevated levels of C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), and interleukin-6 (IL-6) are linked to an increased risk of developing hypertension. This association holds true even at lower inflammation levels, suggesting a continuous risk relationship.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Epidemiology
Background:
- Hypertension is a major global health concern with complex etiology.
- Inflammation is increasingly recognized as a contributing factor to cardiovascular diseases, including hypertension.
- Understanding the role of specific inflammation markers can inform risk prediction and prevention strategies.
Purpose of the Study:
- To systematically evaluate the association between circulating inflammation markers and the future risk of hypertension.
- To quantify the risk of hypertension associated with C-reactive protein (CRP), high-sensitive CRP (hs-CRP), interleukin-6 (IL-6), and IL-1β.
- To explore potential dose-response relationships between inflammation markers and hypertension risk.
Main Methods:
- A systematic literature search was conducted in PubMed and Scopus up to July 10, 2018.
- Included studies were prospective and retrospective cohorts examining the association of CRP, hs-CRP, IL-6, and IL-1β with hypertension incidence in the general population.
- Relative risks (RRs) were calculated using fixed-effects/random-effects models, and non-linear dose-response associations were tested.
Main Results:
- Fourteen prospective cohorts, two retrospective cohorts, and five nested case-control studies involving over 142,000 participants were analyzed.
- Higher CRP levels (RR 1.23) and hs-CRP (RR 1.20) were associated with increased hypertension risk.
- Elevated IL-6 (RR 1.51) also showed a significant association, while IL-1β did not reach statistical significance (RR 1.22).
- A linear dose-response relationship was observed, indicating that hypertension risk increases with rising levels of these inflammation markers.
Conclusions:
- Circulating C-reactive protein (CRP), high-sensitive CRP (hs-CRP), and interleukin-6 (IL-6) are significantly associated with an increased risk of developing hypertension.
- The association between inflammation markers and hypertension risk is evident even within low and intermediate risk categories.
- These findings underscore the importance of inflammation in hypertension pathogenesis and suggest potential targets for risk stratification and intervention.
Objective:
To systematically assess the association of circulating inflammation markers with the future risk of hypertension.
Methods:
We did a systematic literature search of PubMed and Scopus, from database inception to July 10, 2018. Prospective and retrospective cohort studies evaluating the association of circulating C reactive protein (CRP), high-sensitive CRP (hs-CRP), interleukin 6 (IL-6) and IL-1β to the risk of developing hypertension in the general population were included. The relative risks (RRs) for the top versus bottom tertiles of circulating biomarkers were calculated using a fixed-effects/random-effects model. A potential non-linear dose-response association was tested.
Results:
Fourteen prospective cohort studies, two retrospective cohort studies and five nested case-control studies involving 142 640 participants and 20 676 cases were identified. The RR for the third versus first tertiles of circulating CRP was 1.23 (95% CI 1.11 to 1.35; I2=59%, n=12). The association remained unchanged after adjustment for body mass index. The RRs for other biomarkers were as follows: hs-CRP (RR 1.20, 95% CI 1.02 to 1.37; I2=74%, n=7), IL-6 (RR 1.51, 95% CI 1.30 to 1.71; I2=0%, n=5), and IL-1β (RR 1.22, 95% CI 0.92 to 1.51; I2=0%, n=3). A non-linear dose-response meta-analysis demonstrated that the risk of hypertension increased linearly with increasing circulating inflammation markers, even within the low-risk and intermediate-risk categories.
Conclusions:
Higher levels of circulating CRP, hs-CRP and IL-6, but not IL-1β, were associated with the risk of developing hypertension. The association persisted in subgroups of studies defined by major sources of heterogeneity.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
06:26Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI
Published on: November 27, 2019
Related Concept Videos
Inflammation
Hypertension III: Clinical Manifestations and Diagnostic Studies
Relative Risk
Directing Effect of Substituents: meta-Directing Groups
Hypertension I: Introduction
Hypertension II: Pathophysiology